WHI Estrogen-Plus-Progestin Trial: 3 Years Later
Increased risk for adverse cardiovascular outcomes and invasive breast cancer — and reduced risk for fractures and colorectal cancer — did not persist after women discontinued HT.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)